false 0000072444 0000072444 2025-05-12 2025-05-12
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):    May 12, 2025
 
Vaxart, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
 
001-35285
 
59-1212264
(State or other jurisdiction of
incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
         
170 Harbor Way, Suite 300, South San Francisco, California
 
94080
(Address of principal executive offices)
 
(Zip Code)
 
 
Registrant’s telephone number, including area code:    (650) 550-3500
 
 
 
Not Applicable
 
 
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common Stock,$0.0001 par value
 
VXRT
 
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging Growth Company                   
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                    ☐
 
 

 
Item 8.01
Other Events.
 
On May 12, 2025, Vaxart, Inc. (the “Company”) issued a press release that included frequently asked questions and applicable answers with respect to the proposed reverse stock split to be voted on at the Company’s upcoming 2025 Annual Meeting of Stockholders. The Company’s 2025 Annual Meeting will take place on Wednesday, May 21, 2025.
 
A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K.
 
 

 
Item 9.01
Financial Statements and Exhibits.
 
Exhibit No.
 
Description
99.1
 
Press Release, dated May 12, 2025.
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: May 12, 2025
 
VAXART, INC.
     
   
/s/ Steven Lo
   
Steven Lo
   
President and Chief Executive Officer